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Background: To assess antivascular effects, and evaluate clinically translatable magnetic resonance imaging (MRI) biomarkers of
tumour response in vivo, following treatment with vanucizumab, a bispecific human antibody against angiopoietin-2 (Ang-2) and
vascular endothelial growth factor-A (VEGF-A).
Methods: Colo205 colon cancer xenografts were imaged before and 5 days after treatment with a single 10mgkg 1 dose of
either vanucizumab, bevacizumab (anti-human VEGF-A), LC06 (anti-murine/human Ang-2) or omalizumab (anti-human IgE control).
Volumetric response was assessed using T2-weighted MRI, and diffusion-weighted, dynamic contrast-enhanced (DCE) and
susceptibility contrast MRI used to quantify tumour water diffusivity (apparent diffusion coefficient (ADC),  106mm2 s 1), vascular
perfusion/permeability (Ktrans, min 1) and fractional blood volume (fBV, %) respectively. Pathological correlates were sought, and
preliminary gene expression profiling performed.
Results: Treatment with vanucizumab, bevacizumab or LC06 induced a significant (Po0.01) cytolentic response compared with
control. There was no significant change in tumour ADC in any treatment group. Uptake of Gd-DTPA was restricted to the tumour
periphery in all post-treatment groups. A significant reduction in tumour Ktrans (Po0.05) and fBV (Po0.01) was determined 5 days
after treatment with vanucizumab only. This was associated with a significant (Po0.05) reduction in Hoechst 33342 uptake
compared with control. Gene expression profiling identified 20 human genes exclusively regulated by vanucizumab, 6 of which are
known to be involved in vasculogenesis and angiogenesis.
Conclusions: Vanucizumab is a promising antitumour and antiangiogenic treatment, whose antivascular activity can be monitored
using DCE and susceptibility contrast MRI. Differential gene expression in vanucizumab-treated tumours is regulated by the
combined effect of Ang-2 and VEGF-A inhibition.
Angiogenesis, the development of new blood vessels to provide a
nutritive blood supply, is a prerequisite for solid tumour growth
and survival (Ferrara and Kerbel, 2005). Angiogenesis is stimulated
and orchestrated by the release of specific growth factors from
tumour cells, endothelial cells or associated macrophages, the
production of which is upregulated by physiological conditions
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associated with tumours, such as hypoxia, and which are associated
with a compromised and chaotic blood supply.
The binding of vascular endothelial growth factor-A (VEGF-A)
to its endothelial receptors is a key driver of tumour progression,
angiogenesis and vascular permeability. Vascular endothelial
growth factor is considered the most potent angiogenic growth
factor, whose expression is also associated with poor prognosis in a
wide range of human cancers (Yancopoulos et al, 2000).
Consequently, a number of antibody and small molecule-based
approaches have been developed to inhibit VEGF signalling.
Of these, the most notable is bevacizumab, a humanised
monoclonal antibody to VEGF-A with marked clinical efficacy
(Hurwitz et al, 2004). Evasive resistance mechanisms to anti-VEGF
monotherapies are, however, proving a clinical challenge to
maintain effective treatment (Bergers and Hanahan, 2008).
The contribution of the Tie-2 receptor ligands angiopoietin-1
(Ang-1) and angiopoietin-2 (Ang-2) to tumour vascular remodel-
ling has also been established (Tait and Jones, 2004). Ang-1 is
expressed by pericytes, smooth muscle cells and fibroblasts, and is
thought to drive vessel stabilisation and maturation (Yancopoulos
et al, 2000). Angiopoietin-2 is primarily secreted by endothelial
cells and stored in Weibel–Palade bodies (Fiedler et al, 2004).
In contrast to Ang-1, Ang-2 destabilises vessel assembly, increases
vessel permeability and induces a state of vascular plasticity,
promoting endothelial cell sprouting and proliferation (Holash
et al, 1999; Maisonpierre et al, 1997; Yancopoulos et al, 2000).
Angiopoietin-2 expression is upregulated in a broad range of
human malignancies (Hu and Cheng, 2009). Strategies that block
the Ang-2 pathway have demonstrated antitumour effects,
providing direct evidence that therapeutic targeting of this pathway
may be of clinical benefit (Oliner et al, 2004; Mazzieri et al, 2011;
Thomas et al, 2013). Importantly, studies adopting a combination
approach using agents targeted against both VEGF and Ang-2
signalling have revealed superior activity over targeting either
pathway alone (Brown et al, 2010; Hashizume et al, 2010). The
interception of multiple angiogenic pathways thus provides both a
complimentary and additive antitumour response.
Vanucizumab (RO5520985 or RG7221, Roche, Penzberg,
Germany), a novel heterodimeric bivalent bispecific human
antibody against Ang-2 and VEGF-A (bevacizumab-based) has
recently been described (Kienast et al, 2013). Preclinical studies
with vanucizumab demonstrated broad efficacy in a wide variety of
tumour models, resulting in tumour growth delay, regression and
an enhancement in chemotherapeutic response. Antiangiogenic
effects of vanucizumab revealed a modulation in the tumour
vasculature, including a reduction in tumour vessel density, mature
vessel architecture, interstitial fluid pressure and inhibition of early
tumour cell dissemination (Kienast et al, 2013; Bessho et al, 2015).
Advances in imaging technologies such as magnetic resonance
imaging (MRI) provide a means of defining noninvasive
quantitative biomarkers to inform on biologically relevant
structure–function relationships in tumours. This enables an
understanding of the behaviour and heterogeneous distribution
of such associations, and informs on response and resistance to
treatment (O’Connor et al, 2008, 2014). For the evaluation of novel
oncology therapeutics, the use of pharmacodynamic biomarkers,
including those afforded by imaging techniques, is now considered
mandatory (Waterton and Pylkkanen, 2012; O’Connor et al, 2016).
In addition to quantifying any therapy-induced volumetric change
in vivo, functional MRI methods can provide additional mechan-
istic insight (Tunariu et al, 2012). Imaging biomarkers for assessing
tumour response require evaluation before they can be deployed in
clinical trials. In particular, the evaluation of imaging–pathology
correlation, and whether changes in the imaging biomarker reflect
desired changes in the underlying pathology, is important to
establish, but can often only meaningfully be studied in animal
models.
Vascular endothelial growth factor inhibitors including bevaci-
zumab have been shown to elicit a tumour antivascular response that
is detectable by dynamic contrast-enhanced (DCE) MRI (O’Connor
et al, 2009; Loveless et al, 2012). However, the most informative
functional imaging biomarker(s) for evaluating treatment response to
combined Ang-2/VEGF blockade have not been established. Here we
have used a multiparametric functional MRI approach to investigate
tumour response to single-dose administration of vanucizumab in the
Colo205 colon cancer xenograft model. The Colo205 model was
selected given its documented sensitivity to Ang-2 and VEGF
inhibition (Kienast et al, 2013; Oliner et al, 2004). The effects of
vanucizumab on vessel perfusion, hypoxia, necrosis, vessel density and
vessel maturation were also evaluated using ex vivo histopathology.
Differences in the sensitivity of functional MRI biomarkers for
assessing tumour response to the dual targeting of Ang-2 and VEGF-
A are revealed. Preliminary analyses of vascular-related tissue
biomarkers associated with tumour response to vanucizumab,
identified by gene expression profiling, are also described.
MATERIALS AND METHODS
Cell culture, tumour propagation and treatment. Colo205
human colorectal cancer cells (ATCC CCL222 sourced in 2011,
Teddington, UK), were cultured in RPMI-1640 medium supple-
mented with 10% fetal bovine serum and 2mM L-glutamine
(Invitrogen, Paisley, UK) and maintained at 37 1C in a humidified
incubator with an atmosphere of 95% air, 5% CO2. Cells were
authenticated by short tandem repeat (STR) profiling by ATCC
and were not passaged for 46 months in our laboratory.
All experiments were performed in accordance with the local
ethical review panel, the UK Home Office Animals (Scientific
Procedures) Act 1986, the United Kingdom National Cancer
Research Institute guidelines for the welfare of animals in cancer
research (Workman et al, 2010), and the ARRIVE guidelines
(Kilkenny et al, 2010). Female NCr nu/nu mice (7–8 weeks old,
Charles River, Margate, UK) were injected with 5 106 Colo205
cells subcutaneously in the right flank. Tumours were selected for
imaging when volumes reached B250mm3, as assessed by
callipers, using the formula for ellipsoid volume, (LW2)/2,
where L and W were the two largest dimensions of the
ellipsoid. Immediately following pretreatment MRI (day 0), mice
were randomised and administered with a single 10mg kg 1
intraperitoneal dose of either vanucizumab (RO5520985,
anti-human/murine Ang-2/anti-human VEGF-A, Roche), bevaci-
zumab (Avastin, anti-human VEGF-A, Roche), LC06
(anti-murine/human Ang-2) (Thomas et al, 2013) or omalizumab
(Xolair, anti-human IgE control, Roche) (Kienast et al, 2013).
Magnetic resonance imaging was repeated 5 days after treatment. An
additional cohort of animals was treated but not imaged to provide
an independent set of tumour samples for gene expression profiling.
MRI data acquisition. Magnetic resonance imaging was
performed on a 7T horizontal bore Bruker microimaging system
(Ettlingen, Germany) using a 3 cm birdcage volume coil.
Anaesthesia was induced with an intraperitoneal injection of
fentanyl citrate (0.315mgml 1) plus fluanisone (10mgml 1
(Hypnorm; Janssen Pharmaceutical Ltd, High Wycombe, UK)),
midazolam (5mgml 1 (Hypnovel; Roche)) and sterile water
(1 : 1 : 2). A lateral tail vein was cannulated with a 27G butterfly
catheter (Hospira, Royal Leamington Spa, Warwickshire, UK) for
remote administration of MRI contrast agents. Mice were
positioned in the coil on a custom-built platform to isolate the
tumour, and their core temperature was maintained at 37 1C with
warm air blown through the magnet bore.
Multi-slice T2-weighted contiguous 1mm thick axial images
were first acquired for localisation and subsequent quantitation of
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the tumour volume. Diffusion-weighted (DW) images were then
acquired from three 1mm thick axial slices across the centre of
the tumour using an echo-planar imaging (EPI) sequence
(3 3 cm field of view, 128 128 matrix, TR¼ 3000ms,
5 b-values ranging from 40 to 700 s mm 2, 4 averages).
Diffusion-weighted MRI exploits the random diffusion of water
molecules to measure changes in tissue cellularity, quantified
through the measurement of the apparent diffusion coefficient
(ADC,  106 mm2 s 1) (Padhani et al, 2009). Diffusion-
weighted MRI is being actively exploited as an early biomarker
of tumour response to targeted therapies (Baker et al, 2012).
Dynamic contrast-enhanced MRI data were then acquired
from the central axial slice using an inversion recovery (IR) true-
FISP sequence with one baseline scan (3 3 cm field of view,
128 96 matrix, TI¼ 25–1451ms, 50 inversion times, TR¼ 2.4
ms, TE¼ 1.2ms, 8 averages), and 60 dynamic scans (TI¼ 109–
924ms, 8 inversion times, TR¼ 2.4ms, TE¼ 1.2ms, scan TR¼ 10
s, 1 average, 601 flip angle, temporal resolution¼ 20 s) acquired
for 3min before and 17min after an i.v. injection of
0.1mmol kg 1 of a clinically approved, low-molecular-weight
contrast agent Gd-DTPA (Magnevist, Schering, Berlin, Ger-
many) (Baker et al, 2012). Dynamic contrast-enhanced MRI
measures contrast agent extravasation from the blood plasma
compartment to the extravascular extracellular compartment,
that is, vascular leakage, typically expressed by the volume
transfer constant Ktrans (min 1). Increasing contrast agent
concentration in the extracellular leakage space is related to
both tumour perfusion and permeability; an effective vascular
targeting drug would however be expected to reduce Ktrans
(Leach et al, 2005).
Susceptibility contrast MRI, using ultrasmall superparamagnetic
iron oxide (USPIO) particles as an intravascular MRI contrast
agent, was performed on a separate cohort of Colo205-bearing
animals. Tumours were imaged at baseline (day 0), and 5 days
post treatment with a single i.p. dose of 10mg kg 1
of vanucizumab (n¼ 6) or omalizumab (n¼ 7). Multigradient-
recalled echo (MGRE) images (TR¼ 200ms, TE¼ 6ms, TEspace¼ 4
ms, 16 averages) were acquired from 3 contiguous 1mm thick
axial slices through the tumour, using a 128 128 matrix over a
3 3 cm field of view. A second set of identical MGRE images were
acquired 2min after intravenous injection of 150 mmolFe kg 1
USPIO particles (P904, Guerbet, Villepinte, France). The USPIOs
create magnetic susceptibility variations in the proximity of
perfused blood vessels, increasing the transverse MRI relaxation
rate R2* of water in the surrounding tissue. Their long intravascular
half-life enables steady-state measurements of tumour R2* to be
made that are used to determine fractional blood volume (fBV, %)
(Robinson et al, 2007).
MRI data analysis. Tumour volumes were determined using
segmentation from regions of interest (ROIs) drawn on
T2-weighted images for each tumour-containing slice, where clear
delineation of tumour from surrounding tissue could be deter-
mined. Diffusion-weighted, DCE and susceptibility contrast MRI
data were fitted on a pixel-by-pixel basis using in-house software
(Imageview, developed in IDL, ITT Visual Information Systems,
Boulder, CO, USA). Diffusion-weighted and MGRE images were
fitted using a Bayesian maximum a posteriori approach, allowing
estimates of the median ADC and USPIO-induced change in R2*
(DR2*) to be calculated, respectively (Walker-Samuel et al, 2009,
2010). Fractional blood volume (%) was subsequently quantified
incorporating the DR2* data, as previously described (Burrell et al,
2011). For DCE MRI analysis, IR true-FISP data were fitted using a
similar approach, utilising the dual-relaxation sensitivity (T1 and
T2) of the pulse sequence and incorporating the Tofts and
Kermode pharmacokinetic model, providing estimates of Ktrans
(Boult et al, 2011). In addition, model-free analysis was used to
derive the initial area under the gadolinium uptake curve from 0 to
60 s after injection of Gd-DTPA (IAUGC60, mMGdmin).
Immunofluorescence and immunohistochemistry. The hypoxia
marker pimonidazole (60mgkg 1; Hypoxyprobe Inc., Burlington,
VT, USA) (Raleigh et al, 1999) was administered intraperitoneally
immediately before the post-treatment MRI session to allow for full
bioreduction in hypoxic tumour regions. Following MRI, Hoechst
33342 (15mgkg 1; Sigma-Aldrich, Poole, UK), a marker for perfused
vessels, was injected via a lateral tail vein (Boult et al, 2011; Baker et al,
2012). After 1min, tumours were rapidly excised and bisected parallel
with the imaging plane, with half of the tumour snap frozen over
liquid nitrogen for immuno/fluorescence microscopy and gene
signature analysis, and the other half fixed in formalin (10% (v/v)
neutral buffered formalin) for subsequent paraffin embedding for
immunohistochemistry and haematoxylin and eosin (H&E) staining.
Fluorescence signals from Hoechst 33342 and reduced
pimonidazole adducts bound with mouse monoclonal
FITC-conjugated antibodies were detected on whole tumour
10 mm thick frozen sections using a motorised scanning stage
(Prior Scientific Instruments, Cambridge, UK) attached to a BX51
microscope (Olympus Optical, London, UK), driven by image
analysis software (CellP, Soft Imaging System, Mu¨nster,
Germany) as previously described (Boult et al, 2011). Sections
were then counterstained with H&E, dehydrated and imaged again
using the same stage coordinates under bright-field illumination.
CD31 was detected on adjacent sections using rat anti-mouse
CD31 antibodies (1 : 100; BD Biosciences, Oxford, UK) and Alexa
546-conjugated goat anti-rat IgG antibody (1 : 500; Invitrogen)
(Boult et al, 2011).
Hand-drawn ROIs were identified on the H&E image to ensure
only tumour was included, and used to quantify the percentage of
Hoechst 33342 uptake (vessel perfusion) and pimonidazole adduct
area (hypoxia) using CellP as previously described (Baker et al,
2012). Microvessel density (MVD) was calculated from the mean
vessel number (CD31) counted in 45 randomly selected high-
power fields ( 100) for each tumour.
a-smooth muscle actin (a-SMA) immunohistochemistry was
performed on 5mm thick formalin-fixed, paraffin-embedded (FFPE)
sections using mouse monoclonal anti-a-SMA antibodies (1 : 500; 1A4,
Sigma-Aldrich) and an anti-mouse HRP-labelled polymer (Dako, Ely,
UK). The percentage of a-SMA-positive stained area was determined
by analysing X5 randomly selected fields at high magnification
( 200) from each tumour section using a colour deconvolution
program in ImageJ (NIH, Bethesda, MD, USA). An adjacent section
was stained with H&E and imaged under bright-field illumination.
The percentage of tumour necrosis was determined using CellP as
previously described (Baker et al, 2012).
Next-generation RNA sequencing. Three to six tumours each
from two independent experiments with the above-mentioned
treatment groups were collected (cohort 1 no MRI, cohort 2 DW
and DCE MRI imaged cohorts). Total RNA was isolated from
frozen xenograft tissues following standard procedures (Qiagen
RNease mini kit, Manchester, UK). RNA integrity was assayed
using the Agilent Bioanalyzer system (Agilent Technologies,
Stockport, UK), quantitated (by Ribogreen or Nanodrop,
Thermo Scientific, Wilmington, DE, USA), and 500 ng of
polyadenylated RNA passing the QC criterion of RIN 47 was
subjected to sequencing library generation using Illumina TruSeq
RNA sample preparation kit v2 (Illumina, Cambridge, UK)
according to the manufacturer’s instructions without modifica-
tion. Final cDNA libraries were analyzed for size distribution,
quantitated by qPCR, and then normalised to 2 nM in
preparation for sequencing. Libraries were clustered using
Illumina TruSeq PE Cluster Kit v3. Finally, the DNA sequence
was determined on the HiSeq2000 using sequencing-by-synthesis
technology via the Illumina TruSeq SBS Kit. For each specimen,
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2 50 bp paired-end sequences were yielded at an approximate
coverage of 50 million paired-end reads.
Processing of RNA sequencing data. All RNASeq samples passed
quality control in terms of number of reads per sample and read
quality. Short reads were aligned to the human and mouse
transcriptome (based on Ensembl v60) using Bowtie2 (Langmead
and Salzberg, 2012). Based on the alignment, reads mapping to
both transcriptomes at the same time were identified and discarded
from further analysis. On average, 70% of the reads mapped to
either transcriptome, with 7% of the reads mapping to both
organisms that were subsequently filtered out. Across all samples,
B80% of the reads mapped to human, whereas 20% mapped to
mouse, likely representing the quantity of human tumour cells
compared to mouse stroma and immune cells. The reads per
kilobase of transcript per million mapped reads (RPKM) were then
computed for each gene as described by Mortazavi et al (2008)
using the gene composite length, that is, the sum of the length
of all non-overlapping exon groups as normalisation factor, using
in-house tools.
Statistical analysis. Statistical analysis of MRI and histological
data was performed with GraphPad Prism 5 (GraphPad Software,
La Jolla, CA, USA). The mean of median values were used for
statistical analysis of all quantitative MRI data, apart from tumour
volumes, where mean values were used. A two-way ANOVA with
Bonferroni correction, nonparametric Wilcoxon matched pairs
signed-rank test or one-way ANOVA with Dunnett’s multiple
comparison test were used where appropriate, with a P-value of
o5% considered significant. The ANOVA was applied on log2-
transformed RPKM values for vanucizumab, bevacizumab or LC06
treated against control samples in order to identify differentially
regulated genes. Multiple comparison correction was implemented
across contrast pairs. Implementation of ANOVA for gene expression
data was via R function aov() (http://www.statmethods.net/stats/
anova.html).
RESULTS
Treatment with vanucizumab slows tumour growth in Colo205
xenografts. Tumour volumes were determined from multislice
T2-weighted MR images before and 5 days post treatment with a
single dose of vanucizumab, bevacizumab, LC06 or omalizumab.
Representative T2-weighted images from all treatment groups are
shown in Figure 1A. Treatment with vanucizumab resulted in a
significant (Po0.01) cytolentic response (mean tumour volume
increased by 52%) compared with control (166%). Treatment with
either bevacizumab or LC06 induced a similar response, with
significantly (Po0.001) lower mean tumour volumes compared
with control (bevacizumab: 56% volume increase; LC06: 74%)
(Figure 1B). No adverse treatment effects were observed in any
cohort.
Noninvasive assessment of tumour response to vanucizumab
using DW and DCE MRI. Diffusion-weighted MRI was used to
explore whether the antitumour effects of vanucizumab resulted in
changes in ADC, an imaging biomarker associated with alterations
in cell density and which typically increases with successful
treatment. The mean ADC for each treatment group, at baseline
and 5 days post treatment, are summarised in Table 1. No
significant treatment-induced changes in mean tumour ADC were
determined for any intervention, and there was no significant
difference in the mean ADC of any treatment group after 5 days of
treatment compared with omalizumab (control) (P40.05).
Dynamic contrast-enhanced MRI was used to assess any vascular
response following treatment with vanucizumab, bevacizumab,
LC06 or omalizumab. Representative parametric maps of Ktrans are
shown in Figure 2A. Colo205 tumours typically exhibited a marked,
heterogeneous distribution of Gd-DTPA contrast agent uptake
before therapy. After treatment, contrast agent uptake was
noticeably restricted to the tumour periphery in all treatment
groups. The quantitative data for Ktrans and IAUGC60 is summarised
in Figure 2B and C. A significant (Po0.05) reduction in both Ktrans
and IAUGC60 was determined in the vanucizumab-treated cohort
only. There was however no significant difference in either DCE
MRI biomarker 5 days post treatment with vanucizumab,
bevacizumab or LC06 when compared with omalizumab (control).
Decreased tumour perfusion following treatment with vanuci-
zumab can be imaged using susceptibility contrast MRI. Repre-
sentative parametric fBV maps acquired before and 5 days post
treatment with either vanucizumab or omalizumab are shown in
Figure 3A. The mean baseline fBV for all the subcutaneous
Colo205 xenografts imaged was 6.1±0.4%. A marked reduction in
USPIO particle delivery was evident in all the tumours following
treatment with vanucizumab, equating to a significant (Po0.01)
reduction in mean tumour fBV after 5 days of treatment
(Figure 3B). The reduction in fBV 5 days post treatment was
significantly (Po0.05) greater in the vanucizumab cohort
( 2.7±0.5%) compared with that determined in the omalizumab
cohort ( 0.7±0.6%).
Histological assessment of the effects of vanucizumab on
perfused vasculature, hypoxia, microvessel density, vessel
maturation and necrosis. Representative images acquired of
each histological marker assessed for all treatment groups and
control tumours are shown in Figure 4A, with the associated
quantitative summary shown in Figure 4B. Composite fluores-
cence images revealed a heterogeneous distribution and negli-
gible overlap of Hoechst 33342 uptake and pimonidazole adduct
formation. Treatment with vanucizumab or bevacizumab
resulted in significantly (Po0.05) lower tumour perfusion
relative to control (vanucizumab: 17±3%; bevacizumab:
15±3%; control: 28±4%). There was no significant difference
in hypoxia in any of the treatment groups compared with
control. A single dose of either vanucizumab or LC06 had no
significant effect on MVD 5 days after treatment compared with
control (vanucizumab: 15±1%; LC06: 16±1%; control:
18±1%). In contrast, treatment with bevacizumab resulted in
significantly (Po0.05) lower mean MVD compared with control
(bevacizumab: 14±1%). Analysis of pericyte coverage revealed
no significant difference in the expression of a-SMA following a
single dose of vanucizumab, bevacizumab or LC06 compared
with control. Haematoxylin and eosin staining revealed small
localised regions of tumour necrosis (o20%) in all treated and
control tumours. There was no significant difference in the mean
percentage necrosis at 5 days post treatment in any treatment
group compared with control.
VEGF-dependent gene expression profiling. A total of 60 mouse
Ensembl genes that could be mapped to human gene symbols were
identified as significantly differentially expressed in the tumour
when vanucizumab-treated tumour samples were compared with
those treated with omalizumab 5 days after treatment and using
the cutoff criteria of Po0.05 and |log2 ratio|40.5 (Figure 5).
Of these, the expression of 20 genes was altered only in the
vanucizumab-treated tumours (Supplementary Figure S1a),
25 were altered by vanucizumab and LC06 only (Supplementary
Figure S1b), 11 altered by vanucizumab and bevacizumab only and
4 were altered by all 3 antibodies relative to control. Where known,
the biological function of the identified genes is indicated in
Figure 5 and Supplementary Figure S1, and whether they had
previously been described as VEGF-A-dependent genes by Brauer
et al (2013).
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DISCUSSION
Targeting tumour angiogenesis is an attractive treatment
strategy, as the majority of solid tumours are dependent on a
functional vascular supply, destruction of a single blood vessel
results in the death of many tumour cells, and drug delivery
issues are reduced as target cells are adjacent to the bloodstream.
Recent studies suggest that adopting a multitargeted approach
against several angiogenic pathways confers a therapeutic
advantage over single-agent monotargeted therapy (Brown
et al, 2010; Hashizume et al, 2010). One such strategy currently
being investigated is the use of vanucizumab, a heterodimeric
bivalent bispecific human antibody against Ang-2 and VEGF-A
(Kienast et al, 2013). The antitumour efficacy of vanucizumab
has been established in a panel of subcutaneous, orthotopic and
patient-derived xenograft tumour models (Kienast et al, 2013;
Bessho et al, 2015). However, as with any novel agent, accurate
preclinical evaluation of the pathophysiological changes that
occur in situ is essential for both the interpretation of therapeutic
effects and in guiding clinical translation. In this regard,
noninvasive MRI affords a range of quantitative imaging
biomarkers that inform on tumour vascular architecture and
function, and are often influenced by therapies targeted against
tumour blood vessels (Tunariu et al, 2012). The aim of the
present study was to investigate tumour response to a single dose
of vanucizumab in vivo using a multiparametric MRI approach,
validated ex vivo using histological methods.
Here we report that single-dose treatment with vanucizumab is
sufficient to induce significant growth delay in the Colo205
xenograft tumour model as early as 5 days post treatment. Our
results confirm that dual targeting of Ang-2 and VEGF-A provides
similar growth inhibition to that achieved by targeting each
pathway alone. We were unable to observe superior efficacy as has
been previously reported following chronic treatment with
vanucizumab in larger, more established Colo205 xenografts
(Kienast et al, 2013).
Quantitation of tumour ADC using DW MRI is being actively
investigated to detect changes in cellularity in response to
treatment (Padhani et al, 2009). Typically, tumour ADC increases
following successful therapy, and is associated with a loss in
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Figure 1. Effects of vanucizumab on tumour progression. (A) Transverse T2-weighted MR images of the central tumour slice acquired from paired
mice bearing Colo205 xenografts before and 5 days after treatment, as indicated. (B) Summary of tumour volume response, determined by
T2-weighted MRI, for each treatment cohort before and 5 days after treatment with vanucizumab, bevacizumab, LC06 or omalizumab (control).
Data points are mean±1 s.e.m., nX6 per treatment, **Po0.01, ***Po0.001, two-way ANOVA with Bonferroni correction.
Table 1. Summary of the quantitative DW MRI data
ADC (106 mm2 s1)
Pre Post
Vanucizumab 729±24 750±87
Bevacizumab 696±27 786±69
LC06 743±22 734±25
Omalizumab 733±13 687±34
Abbreviations: ADC¼ apparent diffusion coefficient; DW MRI¼diffusion-weighted mag-
netic resonance imaging. Estimates of ADC determined from Colo205 xenografts before
and 5 days after treatment with either vanucizumab, bevacizumab, LC06 or omalizumab.
Data are mean±1 s.e.m., nX6 per treatment.
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membrane integrity, an early feature of cellular death and
increased necrosis. For example, single-dose treatment with
bevacizumab has been shown to increase ADC in an orthotopic
breast cancer model after 3 days (Moestue et al, 2013). Here, no
significant difference in the ADC of Colo205 xenografts was
determined following treatment with vanucizumab, bevacizumab
or LC06. This imaging response correlates with the absence of any
differences in pathologically determined tumour necrosis across all
the treatment groups. These results are also in broad agreement
with previous reports of no significant differences in cell apoptosis,
necrosis or proliferative index following chronic treatment with
vanucizumab (Kienast et al, 2013).
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Figure 2. Effects of vanucizumab on tumour vascular perfusion and permeability assessed by dynamic contrast-enhanced MRI. (A) Parametric
Ktrans maps acquired from paired Colo205 xenografts before and 5 days after treatment with vanucizumab, bevacizumab, LC06 or omalizumab
(control), as indicated. (B) Estimates of the transfer constant (Ktrans) and the initial area under the gadolinium uptake curve to 60 s (IAUGC60)
determined from each Colo205 xenograft before and 5 days after treatment with vanucizumab, bevacizumab, LC06 or omalizumab. (C) Summary
of the percentage change in Ktrans determined across all four treatment groups. Data points are mean±1 s.e.m, nX6 per treatment, *Po0.05,
Wilcoxon matched pairs signed-rank test. There was no significant difference in the change in Ktrans 5 days post treatment with vanucizumab,
bevacizumab or LC06 when compared with omalizumab (control) – two-way ANOVA with Bonferroni correction.
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Dynamic contrast-enhanced MRI is the most common functional
application of MRI in clinical oncology. Numerous studies have
shown that, following intravenous injection of a low-molecular-weight
gadolinium-chelated contrast agent, malignant tumours
demonstrate faster and higher levels of signal enhancement than
normal surrounding tissues, a consequence of their typically
hyperpermeable vasculature, and this has underpinned the large
clinical success of DCE MRI in tumour detection and diagnosis.
Dynamic contrast-enhanced MRI has also been extensively used
preclinically and clinically to assess tumour response to
antiangiogenic and vascular disrupting agents (Leach et al, 2005;
O’Connor et al, 2007). Thus, DCE MRI should be amenable to
monitoring dual blockade of Ang-2 and VEGF by vanucizumab,
previously shown to reduce tumour vascular density (Kienast et al,
2013). In the present study, a single 10mg kg 1 dose of
vanucizumab resulted in a significant reduction in both Ktrans
and IAUGC60 in Colo205 xenografts 5 days after treatment. No
similar reduction in DCE MRI biomarkers was determined
following treatment with bevacizumab or LC06. Importantly,
vanucizumab also elicited a significant reduction in perfused
vessels as measured by Hoechst 33342 uptake. Encouragingly,
in the first-in-human phase 1 trial of vanucizumab, which
incorporated DCE MRI, marked reductions in Ktrans were observed
as early as 96 h after initiation of treatment (Hidalgo et al, 2014).
Dynamic contrast-enhanced MRI-derived estimates of vascular
function such as Ktrans and IAUGC60, using a low-molecular-weight
contrast agent, represent compound biomarkers of both tumour
perfusion and permeability (Leach et al, 2005). Dynamic contrast-
enhanced MRI measurements of tumour response to acute and
chronic anti-VEGF treatment have been varied. Although several
studies have reported a clear decrease in Ktrans consistent with an
antiangiogenic effect (see, e.g., Bradley et al, 2009; O’Connor et al,
2009), others have reported either no change following treatment
(Desar et al, 2011) or a transient and prolonged increase in Ktrans,
attributed to vascular normalisation of surviving vessels
(Batchelor et al, 2007; Moestue et al, 2013). Antiangiogenic therapy
may prune VEGF-dependent neoangiogenic blood vessels, reducing
vascular permeability, but also enhance perfusion through the
remaining normalised vasculature. These opposing effects can thus
make the correct interpretation of treatment-induced changes in DCE
MRI-derived metrics challenging. This can be compounded in
preclinical investigations by the vascular morphology and necrosis
that develops in relatively rapidly growing xenograft models, and
imperfect compartmental data modelling in rodents.
A number of alternative MRI approaches are thus being
exploited to provide simpler yet sensitive imaging biomarkers of
tumour angiogenesis and vascular response, and that may provide
complementary mechanistic insight when used in conjunction with
DCE MRI. One such approach used extensively preclinically is
susceptibility contrast MRI using USPIO particles, enabling
quantitation of fBV (%), and shown to inform on both incipient
tumour angiogenesis (Robinson et al, 2008) and response to
vascular targeted therapies (Persigehl et al, 2007; Robinson et al,
2007). In the present study, treatment with vanucizumab
significantly decreased tumour fBV in vivo compared with
omalizumab (control), also aligning with the significantly lower
tumour uptake of Hoechst 33342. The susceptibility effects
generated by USPIO particles are stronger than gadolinium
chelates used in DCE MRI, and thus arguably may provide a
more sensitive measurement of tumour response to antivascular/
antiangiogenic therapy (Persigehl et al, 2007). Although the clinical
development of P904 has been halted, recent studies have
highlighted the potential off-label use of ferumoxytol as a USPIO
MRI contrast agent in the clinic (Bashir et al, 2015). Quantitation
of tumour fBV, determined using susceptibility contrast MRI with
USPIO particles, used in conjunction with DCE MRI, may thus
provide a more informative approach to assess changes in human
tumour vascular function following treatment within imaging-
embedded clinical trials of novel therapies targeting multiple
angiogenesis pathways, and to delineate any treatment-induced
window of vascular normalisation in vivo.
Tumour vascular normalisation has been shown to occur within
several days of treatment with a VEGF pathway inhibitor (Winkler
et al, 2004). The vascular structural features associated with vessel
normalisation, including reduced tumour MVD and increased
pericyte coverage of the surviving vessels, have been observed
following Ang-2 blockade, and in combination studies targeting
Ang-2 and VEGF (Falco´n et al, 2009; Mazzieri et al, 2011; Daly
et al, 2013). Similarly, chronic treatment with vanucizumab has
previously been shown to lower MVD while increasing pericyte
expression (Kienast et al, 2013). In the present study, no such
histological evidence of vascular normalisation was identified in
Colo205 xenografts following acute single-dose treatment with
vanucizumab, a dose regime that may have elicited a more subtle
angiogenic response to that reported with chronic dosing
(Kienast et al, 2013). Our data did demonstrate a significant
decrease in MVD of Colo205 xenografts following single-dose
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Figure 4. Histological assessment of the effects of vanucizumab on tumour vasculature, hypoxia and necrosis. (A) Composite fluorescence images
of Hoechst 33342 uptake (blue, perfusion) and pimonidazole adduct formation (green, hypoxia) acquired from whole sections of Colo205 xenografts 5 days
after treatment with vanucizumab, bevacizumab, LC06 or omalizumab (control). Fluorescence images (100 magnification) of CD31 immunohistochemistry
used to assess tumour microvessel density (MVD) post treatment. High-magnification ( 200) images of a-SMA immunohistochemical staining used to
assess pericyte coverage. Composite images of whole tumour sections stained with H&E used to assess necrosis. (B) Summary of treatment-induced changes
in perfused tumour vessels, hypoxia, MVD, vascular maturation and necrosis. Data points are mean±1 s.e.m., nX5 tumours per treatment, *Po0.05,
**Po0.01, one-way ANOVA with Dunnett’s multiple comparison test.
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treatment with bevacizumab, a similar response to that reported
across a number of preclinical tumour models (see, e.g.,
O’Connor et al, 2009; Moestue et al, 2013). However, others
have demonstrated no such acute effect of bevacizumab on
tumour MVD (Yuan et al, 1996; Turley et al, 2012). The
dose scheduling for bevacizumab appears to be important, as
chronic dosing has been shown to reduce MVD whereas single
administration demonstrated no effect (Yuan et al, 1996).
In the absence of VEGF, Ang-2 expression can lead to
vessel regression (Maisonpierre et al, 1997; Lobov et al, 2002).
Furthermore, targeting Ang-2 in Colo205 xenografts is insuffi-
cient to alter MVD (Hashizume et al, 2010). It is clear
that when considering the highly complex network of angiogenic
pathways, the effect on vessel development when targeting
single or multiple factors is context, dose and/or time
dependent.
During antiangiogenic therapy, dynamic changes in
vessel perfusion often result in modifications to tumour
oxygenation. Herein, treatment-induced reductions in vessel
perfusion (significant with vanucizumab and bevacizumab),
as measured by Hoechst 33342 uptake, were associated
with a nonsignificant increase in hypoxia in all treatment
groups compared with control. Previous work has shown
that vanucizumab causes a transient increase in expression of
the hypoxia-regulated protein carbonic anhydrase 9 (CAIX)
after 10 days of treatment in Colo205 xenografts.
This upregulation, presumed to be due to increased hypoxia,
may precede and then drive the phenotypic changes associated
with vessel normalisation that were observed at later time
points (Kienast et al, 2013). Similarly, Ang-2 blockade has
also been shown to increase tumour hypoxia after a
2-week dosing schedule (Mazzieri et al, 2011). Our results
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Figure 5. Differential gene expression in vanucizumab-treated tumours. Comparison of vanucizumab-treated tumours with omalizumab (control
(ctrl)) tumour samples 5 days (5dy) after treatment led to the identification of 60 significant (*Po0.05 and |log2 ratio|40.5) differentially expressed
genes in the tumour stroma. The upper part of the Table shows a comparison with the respective results in the other treatment groups, whereas
the colour code specifies if the gene was identified from cohort 1 (C1), cohort 2 (C2) or both. A total of 26 of all genes were previously described in
the VEGF-dependent vasculature signature (Brauer et al, 2013). Where known, the particular biological process in which a gene is known to be
involved with is indicated.
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suggest that after 5 days of treatment, decreased perfusion
may be influencing early changes in tumour oxygenation
that in turn may contribute to the observed antitumour
activity.
Gene expression profiling of tumour tissues led to the
identification of 45 human genes that were differentially
expressed after vanucizumab treatment, but were not signifi-
cantly changed by bevacizumab in this study, thereby
representing genes that could explain different treatment effects
induced by the two antibodies. Differential expression of 20
genes exclusively in the vanucizumab-treated tumours appeared
to be regulated by the combined effect of Ang-2 and VEGF-A
inhibition. The expression of 25 other genes was also affected
by treatment with LC06, potentially indicating that this
regulation is driven by the LC06 component of vanucizumab.
Many of the genes are known to be involved in angiogenesis,
blood vessel development and/or endothelial cell movement.
Other genes have been implicated in microtubule rearrange-
ments or other extracellular processes. Several genes had been
previously described as being VEGF-A dependent (Brauer et al,
2013), but were not identified in the bevacizumab-treated
tumours herein. One explanation for this discrepancy is that
Brauer et al (2013) used B20-4.1.1 (anti-VEGFA) that is
crossreactive with both human and mouse VEGF-A, whereas
bevacizumab only targets human VEGF-A. The present results
also suggest that these genes are not specifically regulated
by bevacizumab, but can also be affected by other antiangio-
genic treatments such as anti-Ang2 (LC06), or combined
human Ang-2 and VEGF-A inhibition by vanucizumab.
Additional tumour models should be profiled to verify the
involvement of these genes in the specific mechanism of action
of vanucizumab.
In conclusion, using multiparametric MRI combined with
ex vivo histology, we have demonstrated that treatment of Colo205
xenografts with vanucizumab results in significant antitumour
activity associated with a significant reduction in functional
tumour vasculature. Gene expression profiling of tumour tissues
identified 20 genes that could be specifically attributed to treatment
effects of vanucizumab. Targeting both Ang-2 and VEGF with
vanucizumab represents a potent antiangiogenic treatment strategy
and whose antivascular effects can be monitored in vivo using
DCE MRI. Incorporation of susceptibility contrast MRI measure-
ments into clinical imaging protocols may provide additional
confirmatory evidence of antiangiogenic response to vanucizumab
in human tumours.
ACKNOWLEDGEMENTS
We acknowledge the support received for The Institute of Cancer
Research Cancer Research UK and EPSRC Cancer Imaging Centre
(Grant C1060/A10334) and to the Cancer Research UK Cancer
Imaging Centre (C1090/A16464) in association with the MRC
and Department of Health (England), an MRC Centenary Award
(to LCJB) and F Hoffman La Roche. We thank Allan Thornhill and
his staff for animal care and maintenance.
CONFLICT OF INTEREST
Markus Thomas, Astrid Koehler, Tapan Nayak, Jean Tessier, Chia-
Huey Ooi, Fabian Birzele, Anton Belousov, Magdalena Zajac,
Carsten Horn and Clare LeFave were employees of the Roche
Group at the time of the study.
REFERENCES
Baker LC, Boult JK, Walker-Samuel S, Chung YL, Jamin Y, Ashcroft M,
Robinson SP (2012) The HIF-pathway inhibitor NSC-134754 induces
metabolic changes and anti-tumour activity while maintaining vascular
function. Br J Cancer 106: 1638–1647.
Bashir MR, Bhatti L, Marin D, Nelson RC (2015) Emerging applications
for ferumoxytol as a contrast agent in MRI. J Magn Reson Imaging 41:
884–898.
Batchelor T, Sorensen A, di Tomaso E, Zhang W, Duda D, Cohen K, Kozak K,
Cahill D, Chen P, Zhu M, Ancukiewicz M, Mrugala M, Plotkin S,
Drappatz J, Louis D, Ivy P, Scadden D, Benner T, Loeffler J, Wen P, Jain R
(2007) AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor,
normalizes tumor vasculature and alleviates edema in glioblastoma
patients. Cancer Cell 11: 83–95.
Bergers G, Hanahan D (2008) Modes of resistance to anti-angiogenic therapy.
Nat Rev Cancer 8: 592–603.
Bessho H, Wong B, Huang D, Tan J, Ong CK, Iwamura M, Hart S, Dangl M,
Thomas M, Teh BT (2015) Effect of Ang-2-VEGF-A bispecific antibody in
renal cell carcinoma. Cancer Invest 33: 378–386.
Boult JKR, Walker-Samuel S, Jamin Y, Leiper JM, Whitley GS, Robinson SP
(2011) Active site mutant dimethylarginine dimethylaminohydrolase 1
expression confers an intermediate tumour phenotype in C6 gliomas
J Pathol 225: 344–352.
Bradley DP, Tessier JJ, Lacey T, Scott M, Ju¨rgensmeier JM, Odedra R, Mills J,
Kilburn L, Wedge SR (2009) Examining the acute effects of cediranib
(RECENTIN, AZD2171) treatment in tumor models: a dynamic contrast-
enhanced MRI study using gadopentate. Magn Reson Imaging 27:
377–384.
Brauer MJ, Zhuang G, Schmidt M, Yao J, Wu X, Kaminker JS, Jurinka SS,
Kolumam G, Chung AS, Jubb A, Modrusan Z, Ozawa T, James CD,
Phillips H, Haley B, Tam RNW, Clermont AC, Cheng JH, Yang SX,
Swain SM, Chen D, Scherer SJ, Koeppen H, Yeh R-F, Yue P, Stephan J-P,
Hegde P, Ferrara N, Singh M, Bais C (2013) Identification and analysis of
in vivo VEGF downstream markers link VEGF pathway activity with
efficacy of anti-VEGF therapies. Clin Cancer Res 19: 3681–3692.
Brown JL, Cao ZA, Pinzon-Ortiz M, Kendrew J, Reimer C, Wen S, Zhou JQ,
Tabrizi M, Emery S, McDermott B, Pablo L, McCoon P, Bedian V,
Blakey DC (2010) A human monoclonal anti-ANG2 antibody leads to
broad antitumor activity in combination with VEGF inhibitors and
chemotherapy agents in preclinical models. Mol Cancer Ther 9: 145–156.
Burrell JS, Walker-Samuel S, Baker LC, Boult JK, Ryan AJ, Waterton JC,
Halliday J, Robinson SP (2011) Investigating temporal fluctuations
in tumor vasculature with combined carbogen and ultrasmall
superparamagnetic iron oxide particle (CUSPIO) imaging. Magn Reson
Med 66: 227–234.
Daly C, Eichten A, Castanaro C, Pasnikowski E, Adler A, Lalani AS,
Papadopoulos N, Kyle AH, Minchinton AI, Yancopoulos GD, Thurston G
(2013) Angiopoietin-2 functions as a Tie2 agonist in tumor models, where
it limits the effects of VEGF inhibition. Cancer Res 73: 108–118.
Desar IM, ter Voert EG, Hambrock T, van Asten JJ, van Spronsen DJ,
Mulders PF, Heerschap A, van der Graaf WT, van Laarhoven HW,
van Herpen CM (2011) Functional MRI techniques demonstrate early
vascular changes in renal cell cancer patients treated with sunitinib: a pilot
study. Cancer Imaging 11: 259–265.
Falco´n BL, Hashizume H, Koumoutsakos P, Chou J, Bready JV, Coxon A,
Oliner JD, McDonald DM (2009) Contrasting actions of selective
inhibitors of angiopoietin-1 and angiopoietin-2 on the normalization of
tumor blood vessels. Am J Pathol 175: 2159–2170.
Ferrara N, Kerbel RS (2005) Angiogenesis as a therapeutic target. Nature 438:
967–974.
Fiedler U, Scharpfenecker M, Koidl S, Hegen A, Grunow V, Schmidt JM,
Kriz W, Thurston G, Augustin HG (2004) The Tie-2 ligand angiopoietin-2
is stored in and rapidly released upon stimulation from endothelial cell
Weibel-Palade bodies. Blood 103: 4150–4156.
Hashizume H, Falco´n BL, Kuroda T, Baluk P, Coxon A, Yu D, Bready JV,
Oliner JD, McDonald DM (2010) Complementary actions of inhibitors of
angiopoietin-2 and VEGF on tumor angiogenesis and growth. Cancer Res
70: 2213–2223.
Hidalgo M, Le Tourneau C, Massard C, Boni V, Calvo E, Albanell J, Taus A,
Sablin M-P, Varga A, Bahleda R, Krieter O, Markovtsova L, Carlile D,
Lahr A, Nayak T, Lechner K, Koehler A, van Uffelen I, Garcia MM (2014)
BRITISH JOURNAL OF CANCER Tumour response to dual inhibition of Ang-2 and VEGF-A
10 www.bjcancer.com |DOI:10.1038/bjc.2016.236
Results from the first-in-human (FIH) phase 1 study of RO5520985
(RG7221), a novel bispecific human anti-ANG-2/anti-VEGF-A antibody,
administered as an intravenous infusion to patients with advanced solid
tumours. J Clin Oncol 32: 2525.
Holash J, Wiegand SJ, Yancopoulos GD (1999) New model of tumor
angiogenesis: dynamic balance between vessel regression and growth
mediated by angiopoietins and VEGF. Oncogene 18: 5356–5362.
Hu B, Cheng SY (2009) Angiopoietin-2: development of inhibitors for cancer
therapy. Curr Oncol Rep 11: 111–116.
Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J,
Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G,
Rogers B, Ross R, Kabbinavar F (2004) Bevacizumab plus irinotecan,
fluorouracil, and leucovorin for metastatic colorectal cancer. New Eng J
Med 350: 2335–2342.
Kienast Y, Klein C, Scheuer W, Raemsch R, Lorenzon E, Bernicke D,
Herting F, Yu S, The HH, Martarello L, Gassner C, Stubenrauch KG,
Munro K, Augustin HG, Thomas M (2013) Ang-2-VEGF-A
CrossMab, a novel bispecific human IgG1 antibody blocking
VEGF-A and Ang-2 functions simultaneously, mediates potent
antitumor, antiangiogenic, and antimetastatic efficacy. Clin Cancer
Res 19: 6730–6740.
Kilkenny C, Browne WJ, Cuthill IC, Emerson M, Altman DG (2010)
Improving bioscience research reporting: the ARRIVE guidelines for
reporting animal research. PLoS Biol 8: e1000412.
Langmead B, Salzberg SL (2012) Fast gapped-read alignment with Bowtie 2.
Nat Methods 9: 357–359.
Leach MO, Brindle KM, Evelhoch JL, Griffiths JR, Horsman MR, Jackson A,
Jayson GC, Judson IR, Knopp MV, Maxwell RJ, McIntyre D, Padhani AR,
Price P, Rathbone R, Rustin GJ, Tofts PS, Tozer GM, Vennart W,
Waterton JC, Williams SR, Workman P (2005) The assessment of
antiangiogenic and antivascular therapies in early-stage clinical trials using
magnetic resonance imaging: issues and recommendations. Br J Cancer 92:
1599–1610.
Lobov IB, Brooks PC, Lang RA (2002) Angiopoietin-2 displays VEGF-
dependent modulation of capillary structure and endothelial cell survival
in vivo. Proc Natl Acad Sci USA 99: 11205–11210.
Loveless ME, Lawson D, Collins M, Nadella MV, Reimer C, Huszar D,
Halliday J, Waterton JC, Gore JC, Yankeelov TE (2012) Comparisons of
the efficacy of a Jak1/2 inhibitor (AZD1480) with a VEGF signaling
inhibitor (cediranib) and sham treatments in mouse tumors using DCE-
MRI, DW-MRI, and histology. Neoplasia 14: 54–64.
Maisonpierre PC, Suri C, Jones PF, Bartunkova S, Wiegand SJ,
Radziejewski C, Compton D, McClain J, Aldrich TH, Papadopoulos N,
Daly TJ, Davis S, Sato TN, Yancopoulos GD (1997) Angiopoietin-2,
a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science
277: 55–60.
Mazzieri R, Pucci F, Moi D, Zonari E, Ranghetti A, Berti A, Politi LS,
Gentner B, Brown JL, Naldini L, De Palma M (2011) Targeting the ANG2/
TIE2 axis inhibits tumor growth and metastasis by impairing angiogenesis
and disabling rebounds of proangiogenic myeloid cells. Cancer Cell 19:
512–526.
Moestue SA, Huuse EM, Lindholm EM, Bofin A, Engebraaten O, Maelandsmo GM,
Akslen LA, Gribbestad IS (2013) Low-molecular contrast agent dynamic
contrast-enhanced (DCE)-MRI and diffusion-weighted (DW)-MRI in
early assessment of bevacizumab treatment in breast cancer xenografts.
J Magn Reson Imaging 38: 1043–1053.
Mortazavi A, Williams BA, McCue K, Schaeffer L, Wold B (2008) Mapping
and quantifying mammalian transcriptomes by RNA-Seq. Nat Methods 5:
621–628.
O’Connor J, Carano R, Clamp A, Ross J, Ho C, Jackson A, Parker G, Rose C,
Peale F, Friesenhahn M, Mitchell C, Watson Y, Roberts C, Hope L,
Cheung S, Reslan H, Go M, Pacheco G, Wu X, Cao T, Ross S, Buonaccorsi G,
Davies K, Hasan J, Thornton P, del Puerto O, Ferrara N, van Bruggen N,
Jayson G (2009) Quantifying antivascular effects of monoclonal antibodies to
vascular endothelial growth factor: insights from imaging. Clin Cancer Res 15:
6674–6682.
O’Connor JPB, Jackson A, Asselin M-C, Buckley DL, Parker GJM, Jayson GC
(2008) Quantitative imaging biomarkers in the clinical development of
targeted therapeutics: current and future perspectives. Lancet Oncol 9:
766–776.
O’Connor JPB, Jackson A, Parker GJM, Jayson GC (2007) DCE-MRI
biomarkers in the clinical evaluation of antiangiogenic and vascular
disrupting agents. Br J Cancer 96: 189–195.
O’Connor JPB, Rose CJ, Waterton JC, Carano RAD, Parker GJM, Jackson A
(2014) Imaging intratumor heterogeneity: role in therapy response,
resistance, and clinical outcome. Clin Cancer Res 21: 249–257.
O’Connor JPB, Aboagye EO, Adams JE, Aerts HJWL, Barrington SF, Beer AJ,
Boellaard R, Bohndiek SE, Brown G, Brady M, Buckley DL, Chenevert TL,
Clarke LP, Collette S, Cook GJ, de Souza N, Dickson JC, Dive C,
Evelhoch JL, Faivre-Finn C, Gallagher FA, Gilbert FJ, Gillies RJ, Goh V,
Griffiths JR, Groves AM, Halligan S, Harris AL, Hoekstra OS, Huang EP,
Hutton BF, Jackson EF, Jayson GC, Jones A, Koh D-M, Lacombe D,
Lambin P, Lassau N, Leach MO, Lee T-Y, Leen EL, Lewis JS, Liu Y,
Lythgoe MF, Manoharan P, Maxwell RJ, McShane LM, Miles KA,
Morgan B, Morris S, Ng T, Padhani AR, Parker GJM, Partridge M,
Pathak AP, Peet AC, Punwani S, Reynolds AR, Robinson SP, Shankar LK,
Sharma RA, Solovie D, Stroobants S, Sullivan DC, Taylor SA, Tofts PS,
Tozer GM, van Herk M, Walker-Samuel S, Wason J, Williams KJ,
Workman P, Yankeelov TE, Brindle KM, Jackson A, Waterton JC (2016)
Imaging biomarker roadmap for cancer studies. Nat Rev Clin Oncol.
in press.
Oliner J, Min H, Leal J, Yu D, Rao S, You E, Tang X, Kim H, Meyer S, Han SJ,
Hawkins N, Rosenfeld R, Davy E, Graham K, Jacobsen F, Stevenson S,
Ho J, Chen Q, Hartmann T, Michaels M, Kelley M, Li L, Sitney K,
Martin F, Sun JR, Zhang N, Lu J, Estrada J, Kumar R, Coxon A, Kaufman S,
Pretorius J, Scully S, Cattley R, Payton M, Coats S, Nguyen L, Desilva B,
Ndifor A, Hayward I, Radinsky R, Boone T, Kendall R (2004) Suppression of
angiogenesis and tumor growth by selective inhibition of angiopoietin-2.
Cancer Cell 6: 507–516.
Padhani A, Liu G, Koh D, Chenevert T, Thoeny H, Takahara T, Dzik-Jurasz A,
Ross B, Van Cauteren M, Collins D, Hammoud D, Rustin G, Taouli B,
Choyke P (2009) Diffusion-weighted magnetic resonance imaging as a cancer
biomarker: consensus and recommendations. Neoplasia 11: 102–125.
Persigehl T, Bieker R, Matuszewski L, Wall A, Kessler T, Kooijman H,
Meier N, Ebert W, Berdel WE, Heindel W, Mesters RM, Bremer C (2007)
Antiangiogenic tumor treatment: early noninvasive monitoring with
USPIO-enhanced MR imaging in mice. Radiology 244: 449–456.
Raleigh J, Chou S, Arteel G, Horsman M (1999) Comparisons among
pimonidazole binding, oxygen electrode measurements, and radiation
response in C3H mouse tumors. Radiat Res 151: 580–589.
Robinson SP, Howe FA, Griffiths JR, Ryan AJ, Waterton JC (2007)
Susceptibility contrast magnetic resonance imaging determination of
fractional tumor blood volume: a noninvasive imaging biomarker of
response to the vascular disrupting agent ZD6126. Int J Radiat Oncol Biol
Phys 69: 872–879.
Robinson SP, Ludwig C, Paulsson J, O¨stman A (2008) The effects of
tumor-derived platelet-derived growth factor on vascular morphology
and function in vivo revealed by susceptibility MRI. Int J Cancer 122:
1548–1556.
Tait CR, Jones PF (2004) Angiopoietins in tumours: the angiogenic switch
J Pathol 204: 1–10.
Thomas M, Kienast Y, Scheuer W, Ba¨hner M, Kaluza K, Gassner C, Herting F,
Brinkmann U, Seeber S, Kavlie A, Welschof M, Ries S, Weidner KM,
Regula JT, Klein C (2013) A novel angiopoietin-2 selective fully human
antibody with potent anti-tumoral and anti-angiogenic efficacy and
superior side effect profile compared to Pan-Angiopoietin-1/-2 inhibitors.
PLoS One 8: e54923.
Tunariu N, Kaye SB, deSouza NM (2012) Functional imaging: what evidence
is there for its utility in clinical trials of targeted therapies? Br J Cancer
106: 619–628.
Turley RS, Fontanella AN, Padussis JC, Toshimitsu H, Tokuhisa Y, Cho EH,
Hanna G, Beasley GM, Augustine CK, Dewhirst MW, Tyler DS (2012)
Bevacizumab-induced alterations in vascular permeability and drug
delivery: a novel approach to augment regional chemotherapy for in-
transit melanoma. Clin Cancer Res 18: 3328–3339.
Walker-Samuel S, Orton M, McPhail LD, Boult JKR, Box G, Eccles SA,
Robinson SP (2010) Bayesian estimation of changes in transverse
relaxation rates. Magn Reson Med 64: 914–921.
Walker-Samuel S, Orton M, McPhail LD, Robinson SP (2009) Robust
estimation of the apparent diffusion coefficient (ADC) in heterogeneous
solid tumors. Magn Reson Med 62: 420–429.
Waterton JC, Pylkkanen L (2012) Qualification of imaging biomarkers for
oncology drug development. Eur J Cancer 48: 409–415.
Winkler F, Kozin SV, Tong RT, Chae SS, Booth MF, Garkavtsev I, Xu L,
Hicklin DJ, Fukumura D, di Tomaso E, Munn LL, Jain RK (2004) Kinetics
of vascular normalization by VEGFR2 blockade governs brain tumor
Tumour response to dual inhibition of Ang-2 and VEGF-A BRITISH JOURNAL OF CANCER
www.bjcancer.com |DOI:10.1038/bjc.2016.236 11
response to radiation: role of oxygenation, angiopoietin-1, and matrix
metalloproteinases. Cancer Cell 6: 553–563.
Workman P, Aboagye EO, Balkwill F, Balmain A, Bruder G, Chaplin DJ,
Double JA, Everitt J, Farningham DA, Glennie MJ, Kelland LR, Robinson V,
Stratford IJ, Tozer GM, Watson S, Wedge SR, Eccles SA (2010) Guidelines
for the welfare and use of animals in cancer research. Br J Cancer 102:
1555–1577.
Yancopoulos GD, Davis S, Gale NW, Rudge JS, Wiegand SJ, Holash J (2000)
Vascular-specific growth factors and blood vessel formation. Nature 407:
242–248.
Yuan F, Chen Y, Dellian M, Safabakhsh N, Ferrara N, Jain RK (1996) Time-
dependent vascular regression and permeability changes in established
human tumor xenografts induced by an anti-vascular endothelial growth
factor/vascular permeability factor antibody. Proc Natl Acad Sci USA 93:
14765–14770.
This work is licensed under the Creative Commons
Attribution 4.0 International License. To view a
copy of this license, visit http://creativecommons.org/licenses/by/4.0/
Supplementary Information accompanies this paper on British Journal of Cancer website (http://www.nature.com/bjc)
BRITISH JOURNAL OF CANCER Tumour response to dual inhibition of Ang-2 and VEGF-A
12 www.bjcancer.com |DOI:10.1038/bjc.2016.236
